ClinicalTrials.Veeva

Menu

Feasibility of an Electrical Impedance Tomography Device for Pulmonary Function Testing in ALS Patients

Beth Israel Lahey Health logo

Beth Israel Lahey Health

Status

Completed

Conditions

ALS

Treatments

Diagnostic Test: EIT

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT05287958
R21NS118434 (U.S. NIH Grant/Contract)
2020C-001010

Details and patient eligibility

About

This is an unblinded pilot study to investigate the technical feasibility of using an electrical impedance tomography device for noninvasive pulmonary function monitoring in ALS patients. The study will enroll patients with ALS in one cohort and healthy volunteers in a second cohort that will both undergo EIT imaging with the investigational device prior to and while performing a standard PFT procedure.

Full description

This is an unblinded pilot study to investigate the technical feasibility of using an electrical impedance tomography device for noninvasive pulmonary function monitoring in ALS patients.

For both Cohort I and II, subject participation will require two visits (initial and 3-4 month follow up), which are expected to last approximately 30 minutes. Subjects will undergo EIT imaging with the investigational device prior to and while performing a standard PFT procedure. The actual EIT imaging will last for 10 to 15 minutes.

Enrollment

58 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Cohort I

Inclusion Criteria:

  1. ALS patients able to perform PFT.
  2. ALS patients recommended for PFT.
  3. Subjects capable of giving written informed consent.
  4. Adult, age ≥ 18 years old.

Exclusion Criteria:

  1. Serious psychiatric illnesses.
  2. Presence of an implanted electronic device (e.g. pacemaker, vagal stimulator, deep brain stimulator) or electrodes or electrical wires.
  3. Skin lesions at chest belt placement sites.
  4. Pregnant women.
  5. Patients with primary lung disease, at the discretion of the Investigator.

Cohort II

  1. Subjects capable of giving written informed consent; 2. Subjects capable of performing a PFT; 3. Adult, age ≥ 18 years old 10.2.2 Exclusion Criteria

  2. Serious psychiatric illnesses.

  3. Presence of an implanted electronic device (e.g. pacemaker, vagal stimulator, deep brain stimulator) or electrodes or electrical wires.

  4. Skin lesions at chest belt placement sites.

  5. Pregnant women.

  6. Subjects with primary lung disease, at the discretion of the Investigator.

Trial design

58 participants in 2 patient groups

Healthy
Description:
While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
Treatment:
Diagnostic Test: EIT
ALS
Description:
While no intervention or investigational agent will be used in this study, an EIT system will be used, which is a Non-Significant Risk Device.
Treatment:
Diagnostic Test: EIT

Trial contacts and locations

2

Loading...

Central trial contact

Irene Yator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems